(Reuters) -Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera, removing a key regulatory hurdle for the deal valued at up to $7.3 billion. The FTC granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews of large mergers. The waiting period was originally set to expire on November 7. The clearance means Pfizer can move ahead with its proposed purchase of Metsera without further antitrust review from U.S. regulators. Shares of Pfizer closed about 1.5% higher on Friday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
In healthcare technology, progress isn’t measured only by new tools—it’s measured by confidence. Confidence that systems…
Mumbai (Maharashtra) [India], April 06: Shri Shripad Naik, Minister of State for New & Renewable…
India’s Premier Aerospace & Defence Manufacturing Expo Returns to New Delhi — 8–10 April 2026…
First-time corporator dedicates entire salary and allowances to the Mayor’s Fund, setting a new benchmark…
New Delhi [India], April 04: Honeyy Katiyal, Founder & CEO of Investors Clinic Infratech Pvt.…
New Delhi [India], April 04: In an era marked by unprecedented technological advance, seismic social…